Good news for Lilly as sintilimab hits the spot in lung cancer againEli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s Share XGood news for Lilly as sintilimab hits the spot in lung cancer againhttps://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy optionThe FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected Share XFDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy optionhttps://pharmaphorum.com/news/fda-review-of-lilly-innovents-sintilimab-paves-way-for-cut-price-immunotherapy-option/
Latecomer Lilly throws cash at Innovent PD-1 partnershipEli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights Share XLatecomer Lilly throws cash at Innovent PD-1 partnershiphttps://pharmaphorum.com/news/latecomer-lilly-throws-cash-at-innovent-pd-1-partnership/
